SciTech Development Appoints John Chapman to Strategic Advisory Board
Key Insights
SciTech Development (search) has appointed John Chapman, formerly of KPMG, to its Strategic Advisory Board as Senior Financial Advisor.
Chapman's expertise includes financial strategy, SEC reporting, IPOs, and M&A, bringing significant value to SciTech's financial operations.
SciTech is currently in Phase 1 clinical trials with ST-001 nanoFenretinide (search) for T-Cell Non-Hodgkin Lymphoma (search).
SciTech Development (search), Inc., a clinical-stage biotechnology company focused on innovative cancer (search) therapeutics, has announced the appointment of John Chapman, CPA, to its Strategic Advisory Board as Senior Financial Advisor. Chapman's extensive background in financial strategy and the pharmaceutical sector is expected to guide SciTech's growth and innovation.
Chapman's Background
John Chapman was a Senior Partner at KPMG, where he served on the Board of Directors for KPMG LLP and KPMG Americas. His career included roles as Global Chair of KPMG's Pharmaceuticals Practice and Global Lead Partner, working with multinational corporations such as Pfizer and Hoechst AG (search). He has advised C-suite executives on complex financial matters, including SEC reporting, initial public offerings, and mergers and acquisitions. Chapman is also recognized as a Financial Expert by the SEC.
Chapman's Perspective
"I am delighted to be joining SciTech Development (search) as a part of their Strategic Advisory Board," said Chapman. "SciTech has an exceptionally talented management team, along with an impressive medical and strategic advisory board. The company's patented lead drug, ST-001 nanoFenretinide (search), has the potential to revolutionize cancer (search) care and bring hope to cancer patients. I am eager to contribute to SciTech's efforts to bring innovative, life-saving treatments to market."
ST-001 nanoFenretinide (search)
ST-001 is a patented, aqueous suspension of nanoparticles containing fenretinide within phospholipid bilayers, designed to enhance bioavailability, delivery, and efficacy for cancer (search) treatment. SciTech is currently in Phase 1 clinical trials for the treatment of T-Cell Non-Hodgkin Lymphoma (search).
Leadership Insight
"With his deep knowledge of the pharmaceutical industry and experience in strategic financial advisory roles, John's insights will be invaluable as SciTech Development (search) advances its lead drug, ST-001, and its cutting-edge drug delivery platform," said Earle Holsapple, CEO of SciTech Development. "John's appointment underscores the company's focus on sustainable financial growth and innovation in the industry."